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Abstract: Ovarian cancer is the main cause of death from gynecological cancer, with its poor
prognosis mainly related to late diagnosis and chemoresistance (acquired or intrinsic) to conventional
alkylating and reactive oxygen species (ROS)-generating drugs. We and others reported that the
availability of cysteine and glutathione (GSH) impacts the mechanisms of resistance to carboplatin in
ovarian cancer. Different players in cysteine metabolism can be crucial in chemoresistance, such as
the cystine/glutamate antiporter system Xc (xCT) and the H2S-synthesizing enzyme cystathionine
β-synthase (CBS) in the pathway of cysteine catabolism. We hypothesized that, by disrupting cysteine
metabolic flux, chemoresistance would be reverted. Since the xCT transporter is also able to take up
selenium, we used selenium-containing chrysin (SeChry) as a plausible competitive inhibitor of xCT.
For that, we tested the effects of SeChry on three different ovarian cancer cell lines (ES2, OVCAR3, and
OVCAR8) and in two non-malignant cell lines (HaCaT and HK2). Results showed that, in addition
to being highly cytotoxic, SeChry does not affect the uptake of cysteine, although it increases GSH
depletion, indicating that SeChry might induce oxidative stress. However, enzymatic assays revealed
an inhibitory effect of SeChry toward CBS, thus preventing production of the antioxidant H2S.
Notably, our data showed that SeChry and folate-targeted polyurea dendrimer generation four
(SeChry@PUREG4-FA) nanoparticles increased the specificity for SeChry delivery to ovarian cancer
cells, reducing significantly the toxicity against non-malignant cells. Collectively, our data support
SeChry@PUREG4-FA nanoparticles as a targeted strategy to improve ovarian cancer treatment, where
GSH depletion and CBS inhibition underlie SeChry cytotoxicity.
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1. Introduction
Ovarian cancer is the leading cause of death from gynecologic cancer [1–3]. This high mortality is
mainly due to late diagnosis and chemotherapy resistance [4–6]. Lack of selective anti-cancer therapy
prompts the use of comprehensive oxidative/alkylating drugs. Ovarian cancer is not an exception,
and carboplatin is applied as a neoadjuvant, adjuvant, and palliative therapy, alone or combined
with taxanes [1,7,8]. The mechanisms of action of platinum drugs are based on the establishment
of adducts of DNA and proteins along with the generation of intracellular reactive oxygen species
(ROS), leading to cell injury and death [9,10]. Chemoresistance against oxidative/alkylating drugs is
associated with alterations in glutathione (GSH) and cysteine dynamics, as well as in cystathionine
β-synthase (CBS)-catalyzed hydrogen sulfide (H2S) biosynthesis [9,11,12]. GSH is the most abundant
low-molecular-weight thiol synthesized in cells, playing a crucial role in the drug detoxification process,
consequently allowing cells to evade cell death [13–19]. Cysteine is the rate-limiting substrate in GSH
production [20,21], and it is also linked to ovarian cancer progression by metabolomics and in vitro
studies [22,23]. Our team showed that high GSH levels underlie ovarian cancer chemoresistance to
carboplatin and that re-sensitization was accomplished by inhibiting GSH synthesis with buthionine
sulfoximine (BSO) [24]. Furthermore, our previous results showed that the clear cell ovarian cancer
histotype relies on cysteine metabolism to adapt to stressful metabolic conditions, such as hypoxia [25].
Additionally, we previously reported cysteine concentration (total and protein bound) in peripheral
blood as a promising marker for screening, early diagnosis, outcome, and follow-up of ovarian
cancer [25]. The overexpression of CBS associated with H2S generation was reported in several ovarian
cancer cell lines and tumor models and was proposed to contribute to mitochondrial morphogenesis
reprogramming [26], energy metabolism regulation [27], and deregulation of lipid metabolism [26],
thereby promoting tumor growth and chemoresistance [12]. Indeed, CBS inhibition may afford
anti-tumor activity and abrogation of chemoresistance via attenuated GSH synthesis and nuclear
metallothionein expression [12,28].
Considering that cysteine is a substrate of CBS and a precursor of GSH, its import must be a
crucial step in H2S generation and GSH synthesis. The cystine/glutamate antiporter system Xc- (xCT)
is pivotal in the exchange of cystine (dimeric cysteine oxidized form) and glutamate, contributing
to cellular homeostasis [23,29,30]. xCT is codified by the soluble carrier protein 7A11-encoding
gene (SLC7A11). Both in physiological conditions and in cancer, xCT expression increases upon
oxidative stress, enhancing cyst(e)ine influx, which in turn increases GSH synthesis and accounts for
chemoresistance [31–34]. Therefore, efforts to develop compounds capable of interfering with xCT
expression or function are a major point of interest [34,35]. Sulfasalazine and erastin were tested with
this purpose, [31,36–38] although their action is not xCT-specific [36,39]. Herein, we hypothesized that
a selenium analogue could be a valuable alternative to directly deplete GSH by inhibiting xCT.
Selenium (Se) is an essential element required for the maintenance of cellular redox balance [40,41]
by being a cofactor of mammalian enzymes such as glutathione peroxidase [40,42]. In addition, selenium
compounds are taken up by cyst(e)ine transporters [40,43,44], and some studies demonstrated that
selenium itself exerts anti-tumoral activity [45,46]. In accordance, in small-cell lung cancer cell lines,
xCT activity was related to higher selenium salt (selenite) sensitivity [47], revealing the possible use of
xCT as a mediator of therapies based on selenium.
Altogether, these observations raised the hypothesis that selenium compounds are good
candidates to impose a competitive inhibition of cyst(e)ine transport into the cell. In this work,
we used selenium–chrysin (SeChry), a compound reported to display anti-tumoral and anti-oxidant
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properties [48–50]. SeChry was tested in two different ovarian cancer cell lines (ES2 and OVCAR3),
and in non-malignant keratinocytes (HaCaT) and proximal tubule epithelial cells (HK2), in order
to unravel its impact on cysteine uptake and carboplatin resistance, as well as its specificity against
malignant cells.
2. Materials and Methods
2.1. Cell Culture
Three human ovarian cancer cells lines were used, serous carcinoma (OSC) cell lines (OVCAR3
HTB-161™ and OVCAR8 CVCL_1629TM) and a clear cell carcinoma (OCCC) cell line (ES2 CRL-1978™).
Additionally, an immortal keratinocyte cell line (HaCaT PCS-200-011™) and a proximal tubular
line derived from normal kidney (HK2 CRL- 2190™) were also tested. All the cell lines were
obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). ES2, OVCAR3,
OVCAR8, and HaCaT cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM;
41965-039, Gibco, Life Technologies, Waltham, MA, USA) and HK2 in Dulbecco’s modified Eagle
medium/Nutrient Mixture F-12 (DMEM-F12; 11320-033, Gibco, Life Technologies). All culture media
were supplemented with 10% fetal bovine serum (FBS; S 0615, Merck, Burlington, VT, USA), 1%
Antibiotic-Antimycotic (AA; P06-07300, PAN Biotech, Aidenbach, Germany) and 50 µg/mL gentamicin
(15750-060, Gibco, Life Technologies). Cells were maintained in a humidified environment of 5%
CO2 at 37 ◦C, until reaching approximately 75–100% optical confluence. Cells were detached with
0.05% trypsin–ethylenediaminetetraacetic acid (EDTA; 25300-054, Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) at room temperature (RT) for approximately 5 min. In cell death assays, cells in
suspension in the culture media (supernatant) were analyzed together with adherent cells after trypsin
harvesting. In all the other experiments, only viable adherent cells were analyzed.
2.2. Quantitative Real-Time PCR
ES2 and OVCAR3 cells (2 × 105 cells/mL) were seeded in 12-well plates (1 mL/well) and cultured
in control condition and exposed to cysteine (0.402 mM; 102839, Merck), carboplatin (0.025 mg/mL;
IPO’s Pharmacy, Lisbon, Portugal), and cysteine combined with carboplatin. Prior to the addition of
the experimental conditions, cells were synchronized under starvation (culture medium without FBS)
for 8 h.
The cells were collected after 16 h of experimental conditions, and RNA extraction was executed
using RNeasy Mini Extraction kit (74,104, Qiagen, Hilden, Germany). The complementary DNA
(cDNA) synthesis from 1 µg of RNA was performed using SuperScript II Reverse Transcriptase
(18080e44, Invitrogen, Waltham, MA, USA). Quantitative real-time PCR was performed using
SYBR Green PCR Master Mix (4309155, Applied Biosystems, Waltham, MA, USA), according
to the manufacturer’s protocol. Real-time PCR was carried out in a Lightcycler®480 System
instrument (05015243001, Roche, Basel, Switzerland). The xCT/SLC7A11 expression was quantified
(forward 5’–GGTCCTGTCACTATTTGGAGC–3’ and reverse 5’–GAGGAGTTCCACCCAGACTC–3’),
and hypoxanthine–guanine phosphoribosyltransferase 1 (HPRT1) was used as a housekeeping gene
(forward 5’–TGACACTGGCAAAACAATG–3’ and reverse 5’–GGTCGTTTTTCACCAGCAA–3’).
2.3. Western Blotting
ES2 and OVCAR3 cells (2.5 × 105 cells/mL) were seeded in six-well plates (2 mL/well), cultured in
control conditions, and exposed to l-cysteine (0.402 mM; 102839, Merck), carboplatin (0.025 mg/mL;
IPO’s Pharmacy), and cysteine combined with carboplatin for 16 h. Prior to the addition of the
experimental conditions, cells were synchronized under starvation.
For total protein extraction, cell pellets were lysed using radio-immunoprecipitation assay (RIPA)
buffer. Protein concentration was determined spectrophotometrically (595 nm) via the Bradford
method, using the Bio-Rad protein assay reagent (500-0006, Bio-Rad, Hercules, RI, USA). After
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the addition of loading buffer containing 10% SDS, 0.5% bromophenol blue in Tris-HCl (pH 6.8),
and 10% β-mercaptoethanol (M3148, Sigma, St. Louis, MO, USA), samples (range of 50–100 µg)
were boiled at 95–100 ◦C for 10 min. Samples were analyzed in 12% PAGE (polyacrylamide gel
electrophoresis). Proteins were transferred to an Immuno-Blot®polyvinylidene fluoride (PVDF)
membrane with a Trans-Blot®TurboTM Blotting system, posteriorly incubated with rabbit anti-human
xCT (ab175186-Abcam, 1:1000) overnight at 4 ◦C, and further incubated with secondary antibody
immunoglobulin G (IgG)-conjugated horseradish peroxidase (HRP; anti-rabbit, 1:5000, 31460, Thermo
Scientific Scientific), for 2 h at RT. After these incubations, specific bands were detected using enhanced
chemiluminescence (ECL) Western blotting substrate (SuperSignal®West Pico Chemiluminescent
Substrate, 34080, Thermo Scientific) in a ChemiDoc XRS System (Bio-Rad) with Image Lab software.
The detection of the endogenous control (β-actin) was also performed (mouse anti-human β-actin;
1:5000, A5441, Sigma and secondary HRP-conjugated; anti-mouse, 1:5000, 31430, Thermo Scientific).
Bands were quantified using Image J software (rsb.info.nih.gov/ij/).
2.4. Immunofluorescence
To analyze the effects of cysteine and/or carboplatin on nuclear factor erythroid 2-related factor 2
(Nrf2) expression and SeChry effect on xCT expression, lamellas were inserted in wells, coated with
0.2% gelatin (G-1890, Sigma Aldrich, St. Louis, MO, USA); then, cells (2 × 105 cells/mL), seeded in
24-well plates (500 µL/well), were submitted to control, cysteine (0.402 mM; 102839, Merck), carboplatin
(0.025 mg/mL; IPO’s Pharmacy), and cysteine combined with carboplatin for 16 h. In SeChry assays, cells
were exposed to SeChry (19 µM, a concentration above the half maximal effective concentration (EC50;
see Figure S1) for 24 h and then, without removing SeChry, exposed to the other experimental conditions
(cysteine and carboplatin) for another 24 h. After this, cells were fixed with 4% paraformaldehyde
(104003, Merck Millipore, Burlington, VT, USA) for 15 min at 4 ◦C. Posteriorly, in order to permeabilize
cells, 0.1% saponin in phosphate-buffered saline PBS (1×) with 0.5% bovine serum albumin (BSA)
was applied to the cells for 15 min at RT. Cells were then incubated with primary antibody (Rabbit
anti-human xCT, ab175186-Abcam; Rabbit anti-human Nrf2, ab62352-Abcam; 1:100 diluted in 0.1%
saponin in PBS (1×) with 0.5% BSA), 3 h at RT, followed by incubation with the secondary antibody
Alexa Fluor®488 anti-rabbit (A-11034, Invitrogen) for 1 h at RT. Slides were mounted in VECTASHIELD
media containing DAPI (4′-6-diamidino-2-phenylindole) (H-1200, Vector Labs, Burlingame, CA, USA).
The analysis was performed by standard fluorescence microscopy using a Zeiss Imajer.Z1 AX10
microscope. Images were acquired and processed with CytoVision software.
2.5. Cell Death Analysis by Flow Cytometry
To examine cell death resultant from carboplatin (0.025 mg/mL; IPO’s Pharmacy) exposure with
and without cysteine (0.402 mM; 102839, Merck) or the carboplatin cysteinyl-S-conjugate (the metabolite
generated upon the catabolism of GSH–carboplatin adduct) [51], cells (2 × 105 cells/mL) were seeded in
24-well (500 µL/well) plates incubated for 16 h. In the case of the SeChry (19 µM, a concentration above
EC50; see Figure S1) effect on cell death, an incubation of 48 h with SeChry was performed, and, in the
last 24 h, cysteine and/or carboplatin were added. After experimental conditions, the supernatants
were collected, and adherent cells were harvested with 0.05% trypsin–EDTA. Cells in the supernatant
and trypsinized cells were joined and centrifuged at 255× g for 2 min. Cells were stained with 0.5 µL
annexin V–fluorescein isothiocyanate (FITC) (640906, BioLegend, San Diego, CA, USA), in annexin V
binding buffer 1×, and incubated at RT, in dark for 15 min. Samples were resuspended in 200 µL PBS
(1×) with0.1% BSA and centrifuged at 255× g for 2 min. Cells were resuspended in 200 µL of annexin
V binding buffer 1×, and 2.5 µL of propidium iodide (PI, 50 µg/mL; P4170, Sigma-Aldrich) was added
5 min prior to analysis. Afterward, samples were analyzed by flow cytometry (FACScalibur, Becton
Dickinson). Data were analyzed using FlowJo 8.7 software (https://www.flowjo.com).
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2.6. High-Performance Liquid Chromatography (HPLC)
The effect of SeChry on cysteine uptake and GSH content was tested in ES2 and OVCAR3 cells
by HPLC with fluorescence detection (FLD). Both the extracellular and the intracellular thiols were
assessed, as the total levels and total free levels. The levels of cysteine (Cys), glutathione (GSH),
and cysteinyl-glycine (CysGly) were assessed according to Grilo and co-authors [52] adapted to cell
culture. The detector was set at excitation and emission wavelengths of 385 and 515 nm, respectively.
The mobile phase consisted of 100 mM acetate buffer (pH 4.5) and methanol (98:2 (v/v)). The analytes
were separated in an isocratic elution mode for 20 min, at a flow rate of 0.6 mL/min.
Cells (2.5 × 105 cells/mL) were cultured in six-well plates (2 mL/well) for 24 h, without starvation
and exposed to SeChry (19 µM, a concentration above EC50; see Figure S1). After this period, cells
were incubated with cysteine (0.402 mM; 102839, Merck) for 30 min and 2 h, and were harvested with
0.05% trypsin–EDTA, centrifuged at 255× g for 2 min, rinsed twice in PBS (1×), and lysed with 120 µL
PBS (1×) with 0.01% (v/v) Triton X-100. Cell lysates and supernatants were centrifuged at 10,600× g for
2 min. The supernatants and the lysates were stored at −80 ◦C.
2.7. Synthesis of SeChry
Selenium-containing chrysin (SeChry) was synthesized following a reported protocol [48]. After
purification, the formation of the product was confirmed by 1H NMR. 1H NMR (CDCl3, 400 MHz) δ
(ppm): 7.96 (2H, d, J = 8.0 Hz), 7.76 (1H, s), 7.61 (1H, t, J = 8.0 Hz), 7.52 (2H, t, J = 8.0 Hz), 6.51 (1H, d,
J = 4.0 Hz), 6.46 (1H, d, J = 4.0 Hz).
SeChry is stable for several months if stored at 4 ◦C under inert atmosphere. Partial deselenization
may occur for storage at room temperature in the presence of oxygen (up to 30% in a two-month
period). No degradation was observed in the culture medium under the experimental conditions of the
performed assays (purity checked by CHCl3 extraction from the medium followed by NMR analysis).
Since SeChry is not water-soluble, fresh SeChry solutions were prepared for all the assays. For
each experiment, a stock solution of 1 M was prepared in 100% dimethyl sulfoxide (DMSO). Afterward,
the appropriate intermediate solutions were also prepared in 100% DMSO in order to use the final
desired concentrations of SeChry with a final concentration of 0.2% DMSO in the cell culture medium.
Accordingly, 0.2% was used in the DMSO control condition.
2.8. Synthesis of Folate-Targeted Polyurea Dendrimer Generation Four (PUREG4-FA) Nanoparticles
Folate-targeted polyurea dendrimer generation four (PUREG4-FA) was prepared by reacting
polyurea dendrimer generation four (PUREG4), obtained using our supercritical-assisted polymerization
protocol [53], with activated folic acid succinic ester (FA-NHS). FA-NHS was synthesized following the
literature [54]. Typically, in a round-bottom flask, 250 mg (0.566 mmol) of folic acid (FA) was dissolved
in DMSO (2.75 mL). After the addition of 130.8 mg (1.137 mmol) of N-hydroxysuccinimide (NHS),
128.5 mg (0.623 mmol) of N,N′-dicyclocarbodiimide (DCC), and 0.15 mL (1.082 mmol) of triethylamine
(TEA), the reaction was stirred at RT overnight in the dark. The product was precipitated and washed
several times with diethyl ether. After drying under vacuum, FA-NHS was obtained as a yellow
powder (263.4 mg) in 86.4% yield. 1H NMR (400 MHz, DMSO-d6) δ (ppm): 8.64 (1H, s), 7.63 (2H, d,
J = 8.0 Hz), 6.64 (2H, d, J = 8.0 Hz), 4.49 (2H, s), 4.28 (1H, s), 2.54 (4H, s), 2.29 (1H, s), 2.03 (1H, s), 1.93
(1H, s).
Next, FA-NHS was conjugated with PUREG4 (via NH2 surface groups) to obtain PUREG4-FA. In a
25-mL round-bottom flask, 100 mg (0.0127 mmol) of PUREG4 was dissolved in 5.0 mL of DMSO. To this
solution, 13.7 mg (0.0254 mmol) of FA-NHS and 6.9 µL (0.0510 mmol) of TEA were added. The reaction
was stirred at RT overnight in the dark. Next, TEA excess was removed on the rotary evaporator, and
diethyl ether was added. The obtained precipitate was dried under vacuum, and PUREG4-FA was
obtained as yellow oil in 93.9% yield. Via NMR, it was found that two molecules of folic acid were
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conjugated to the surface of PUREG4. 1H NMR (400 MHz, D2O) δ (ppm): 8.64 (2H, s), 7.70 (4H, bs),
6.86 (4H, d, J = 8.0 Hz), 4.61 (2H, s), 3.54–3.00 (180H, m), 2.96–2.40 (462H, m).
2.9. Preparation of SeChry@PUREG4-FA Nanoparticles
SeChry was encapsulated in PUREG4-FA nanoparticles following a modified protocol [55]. Briefly,
a CHCl3 solution (0.5 mL) of SeChry (6.5 mg) was added to an aqueous solution (2 mL) of PUREG4-FA
(125 mg). Next, CHCl3 was removed in a rotary evaporator and the mixture allowed stirring at RT
overnight. Then, the aqueous solution was extracted with CHCl3 to remove non-encapsulated
or surface-bound SeChry. No SeChry was found in the CHCl3 extracts (control by thin-layer
chromatography (TLC)), thus confirming a full encapsulation. The release profile followed the
usual profile reported for this nanodelivery system [55].
2.10. Inhibition of H2S-Synthesizing Enzymes by SeChry
The ability of SeChry to inhibit the human H2S-synthesizing enzymes was evaluated by activity
assays carried out with isolated recombinant cystathionine β-synthase (tCBS, a catalytically competent
truncated version lacking the s-adenosyl-l-methionine-responsive regulatory C-terminal domain),
cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (MST). Proteins were produced
and isolated as reported [56]. The H2S-synthesizing assays were performed, employing both the
fluorometric probe 7-azido-4-methylcoumarin (AzMc) and the colorimetric methylene blue (MB)
method [56]. Fluorescence and absorbance readings were recorded in a FLUOstar Optima (BMG
Labtech) plate reader. Whereas the AzMc method was performed in the micro-plate format as
described [56], the MB method was carried out in Eppendorf tubes to allow centrifugation to remove
precipitated protein. SeChry solutions were prepared and diluted in 100% DMSO and added to
all reactions in a 1/100 dilution. Reactions and the respective controls containing all reagents were
performed in triplicate.
2.11. Statistical Analysis
Statistical analyses were performed in GraphPad Prism 7.0 software (www.graphpad.com).
Data are presented as means ± SD. Assays were performed with at least biological three replicates.
For comparisons of two groups, a two-tailed unpaired t-test was used. For more than two groups,
one-way and two-way analyses of variance (ANOVA) with Tukey’s multiple comparisons post hoc test
were used. Statistical significance was established as p < 0.05.
3. Results
3.1. Cysteine Partially Abrogates Platinum-Induced Cell Death and Modulates xCT Expression
Considering our previous observation that cysteine contributes to ovarian cancer cell resistance to
platinum drugs [25,57], we aimed to further evaluate the cysteine protective contribution at different
time points. At 48 h, cysteine was significantly protective to ES2 cells against carboplatin-induced
cell death (Figure 1A). In OVCAR3 cells, at 48 h, there was also a tendency for a protective effect of
cysteine upon carboplatin exposure, albeit not significant (Figure 1B).
As xCT is important to cyst(e)ine uptake (considering that, extracellularly, cysteine is converted to
the oxidized form cystine), we analyzed the expression of xCT/SLC7A11 upon exposure to cysteine and
carboplatin. Cysteine significantly upregulated xCT/SLC7A11, with and without carboplatin, in the
ES2 cell line but not in OVCAR3 (Figure 1C). Considering protein levels, there was a trend to increased
xCT levels upon carboplatin exposure in ES2. In cells exposed solely to carboplatin, the levels tended
to be higher but without statistical significance, whereas, in cells exposed to carboplatin plus cysteine,
xCT levels were significantly increased (Figure 1D). In OVCAR3 cells, no significant differences were
observed in xCT protein levels (Figure 1D).
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Figure 1. Putative involvement of cystine/glutamate antiporter system Xc (xCT) and nuclear factor
erythroid 2-related factor 2 (Nrf2) in the protective effect of cysteine upon platinum salt exposure.
ES2 and OVCAR3 cell lines were incubated with cysteine, carboplatin, and a combination of carboplatin
with cysteine for 16 h (A,B). Cell death was determined by flow cytometry using annexin V fluorescein
isothiocyanate (FITC) and propidium iodide (PI) staining. The xCT/soluble carrier protein 7A11-
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encoding gene (SLC27A11) messenger RA (mRNA) expression was analyzed by RT-qPCR (C).
Hypoxanthine–guanine phosphoribosyltransferase (HPRT) was used as the housekeeping gene. The
xCT protein levels were assessed by Western blotting; β-actin was used as the house-keeping protein
(D). Nrf2 protein levels were measured by immunofluorescence (E,F). Results are shown as means ± SD;
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 (A–D, and F), and represents statistical significance in relation to control
conditions, # p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001 represents statistical significance between conditions, and
&& p ≤ 0.01 represents statistical significance between conditions among cell lines (A–D, and F).
Collectively, these results show that cysteine has a protective effect against carboplatin, mainly in
ES2 cells with a longer period of carboplatin exposure. Moreover, both cysteine and carboplatin can
modulate xCT expression in ES2 at the transcriptional and translational levels, respectively.
3.2. Cysteine and Carboplatin Modulate the Expression of Nrf2
Nrf2 is a transcription factor involved in redox homeostasis, which is overexpressed upon oxidative
stress, and it is described as the main activator of xCT/SLC7A11 [29,58–60]. Immunofluorescence
analysis showed that carboplatin exposure significantly upregulated Nrf2 levels in both cell lines
(Figure 1E,F). In ES2, a synergy between the effects of cysteine and carboplatin was observed given
their cumulative effect on Nrf2 levels.
3.3. SeChry Induces Cell Death and xCT Expression in Ovarian Cancer Cells
SeChry was previously reported as having a cytotoxic effect on cancer cells with the ability to
overcome cisplatin resistance and multiple drug resistance (MDR) [48–50]. As a selenium-containing
small molecule, we hypothesized that it could function as a competitor of cyst(e)ine for xCT binding
and transport. Considering that the ability of cyst(e)ine uptake contributes to chemoresistance, blocking
xCT with SeChry could revert this chemoresistance phenomenon. Thus, we firstly aimed to disclose
the impact of SeChry on cell death upon cysteine and/or carboplatin exposure. For this, SeChry was
tested (48 h) with and without cysteine or carboplatin exposure (24 h). The effect of carboplatin was
tested for 24 h, since, at this time point, carboplatin does not significantly affect cell viability, which
allowed us to analyze the effect of SeChry on cell death and possible synergistic or antagonistic effects.
In addition to ES2 and OVCAR3, we also tested this compound on HaCaT, a keratinocyte cell line,
due to its recognized sensibility to compounds containing selenium, and on HK2, a kidney tubular
cell line, due to the susceptibility of renal cells to platinum salt injury. In ES2 and OVCAR3, SeChry
alone or combined with cysteine showed increased cell death levels compared to control conditions
(Figure 2A,B). However, SeChry toxicity was abrogated by carboplatin, independently of the presence
of cysteine (Figure 2A,B). In turn, HaCaT and HK2 cell lines presented augmented cell death in all
SeChry conditions (Figure 2C,D).
To test the effects of SeChry on xCT/SLC7A11 expression, protein levels were assessed by
immunofluorescence. Interestingly, in all cell lines, xCT expression increased upon exposure to SeChry
alone or combined with cysteine or carboplatin (Figure 2E).
So far, results indicate that SeChry induces cell death and xCT/SLC7A11 expression in both ovarian
cancer cells and non-malignant cells. However, contrarily to what was expected, SeChry does not
allow the chemoresistance reversion in ovarian cancer cells. Instead, SeChry cytotoxicity decreased
upon carboplatin exposure.
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and SeChry combined with cysteine and/or carboplatin for 24 h and 48 h of SeChry exposure (A–D).
Cell death was analyzed by flow cytometry using annexin V–FITC and propidium iodide (PI) staining.
The xCT protein levels were evaluated by immunofluorescence (E). Results are shown as means ± SD;
*** p < 0.001, and represents statistical significance in relation to control conditions, and ### p ≤ 0.001
represents statistical significance between conditions (one-way ANOVA, Tukey post-test).
3.4. SeChry Does Not Impair But Enhances Cysteine Uptake
We hypothesized that SeChry induces cell death due to cysteine uptake impairment. To test
this hypothesis, cells were exposed to SeChry with and without cysteine, and the intracellular and
extracellular thiols levels of cell lysates and culture medium (supernatant) were determined by
HPLC-FLD analysis. In both cell lines, SeChry did not impair cysteine uptake, as no significant
differences were found both in intracellular (Figure 3A,B) and extracellular (Figure 3C,D) levels
compared to the control. The only exception was the extracellular total free levels of cysteine in
OVCAR3 cells, which suggested lower cysteine uptake; however, no significant differences in the
intracellular total free levels of cysteine were observed in OVCAR3 cells (Figure 3B,D). Moreover, in ES2
cells and in the presence of cysteine, data indicate that SeChry enhances cysteine uptake, as increased
total and free total intracellular cysteine levels (Figure 3A,B) and decreased total extracellular levels
(Figure 3C) (p < 0.05) were observed, mainly upon 30 min of experimental conditions. In OVCAR3
and in the presence of cysteine, data suggest that SeChry does not enhance cysteine uptake, as no
significant differences in intracellular (Figure 3A,B) and extracellular cysteine levels (Figure 3C,D)
were observed among control and SeChry plus cysteine conditions. Overall, SeChry does not lead to
cysteine uptake impairment; rather, it appears to enhance it, at least in ES2 cells.
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DMSO (control), cysteine, SeChry, and SeChry combined with cysteine. After 24 h of SeChry 
Figure 3. SeChry does not impair cysteine uptake. ES2 and OVCAR3 cell lines were exposed to
DMSO (control), cysteine, SeChry, and SeChry combined with cysteine. After 24 h of SeChry exposure,
cells were incubated with cysteine for 30 min and 2 h. High-performance liquid chromatograph
(HPLC) coupled to fluorescence detection (FLD) was used to measure (A) intracellular total cysteine
concentration, (B) intracellular total free cysteine concentration, (C) total cysteine concentration in the
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culture media (supernatant), and (D) total free cysteine concentration in the supernatant. Results
are shown as means ± SD; * p < 0.05, ** p < 0.01, and represents statistical significance in relation to
control, # p < 0.05, ## p < 0.01, ### p < 0.001 represents statistical significance in relation to cysteine,
“+” represents statistical significance between conditions at the same time point, and &&& p < 0.001
represents statistical significance between conditions among cell lines.
3.5. SeChry Enhances Glutathione (GSH) Turnover
Intra- and extracellular GSH levels and extracellular levels of cysteinyl-glycine (Cys-Gly, a product
of GSH degradation) were evaluated in the absence or presence of SeChry in order to evaluate the
effect of SeChry on the dynamics of GSH synthesis and degradation.
Compared to the control, SeChry led to decreased GSH content, mainly in OVCAR3 cells
(Figure 4A,B). However, in the presence of cysteine, SeChry also decreased GSH content in ES2 cells
(Figure 4A,B). Regarding the extracellular levels, SeChry increased the GSH levels (total and total
free) independently of cysteine, in both cell lines (Figure 4C,D). Furthermore, the same dynamics
were observed for Cys-Gly in ES2 but not in OVCAR3 cells (Figure 4E,F). The data support the fact
that, in addition to not impairing cysteine uptake, SeChry prompts GSH degradation, which involves
transport of GSH to the extracellular compartment where GSH is further degraded into the dipeptide
Cys-Gly through γ-glutamyl-transpeptidase activity. The Cys-Gly/GSH ratio shows that SeChry
stimulates GSH turnover in both ES2 and OVCAR3, with the same pattern (Figure 4G,H).
3.6. SeChry Inhibits Cystathionine β-Synthase (CBS)
As SeChry did not impair or enhance cyst(e)ine uptake, we wondered whether its cytotoxic
effects could be related to the H2S-synthesizing enzymes in the path of cysteine catabolism:
cystathionineβ-synthase (CBS), cystathionineγ-lyase (CSE), and 3-mercapto-pyruvate sulfurtransferase
(MST) [61–63].
Initial attempts to employ the fluorometric AzMc probe to evaluate the inhibition of the human
H2S-synthesizing enzymes by SeChry were hampered by the strong interference of SeChry with the
fluorometric probe, which precluded measuring the enzymatic activity (data not shown). Therefore,
we resorted to the colorimetric methylene blue method. By testing a single SeChry concentration of
200 µM, we observed that tCBS was completely inhibited by SeChry, whereas neither CSE nor MST
were inhibited. The tCBS inhibition was then evaluated as a function of SeChry concentration in
the 0–200-µM range (Figure 5), yielding an apparent half maximal inhibitory concentration (IC50) of
6.3 ± 1.2 µM.
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Figure 4. SeChry induces glutathione (GSH) turnover. ES2 and OVCAR3 cell lines were exposed to
DMSO (control), cysteine, SeChry, and SeChry plus (+) cysteine; after 24 h of SeChry exposure, cells
were incubated with cysteine for 30 min and 2 h. High-performance liquid chromatography (HPLC)
coupled to fluorescence detection was used to measure (A) intracellular total GSH concentration,
(B) intracellular total free GSH concentration, (C) total GSH concentration in the supernatant, (D) total
free GSH concentration in the supernatant, (E) total cysteinyl-glycine (Cys-Gly) concentration in the
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supernatant, (F) total free GSH concentration in the supernatant, and the extracellular ratio of
Cys-Gly/GSH in ES2 (G) and OVCAR3 (H) cells. Results are shown as means ± SD; * p < 0.05, ** p < 0.01,
*** p < 0.001, and represents statistical significance in relation to control, “#” represents statistical
significance in relation to cysteine, # p < 0.05, ## p < 0.01, ### p < 0.001represents statistical significance
between conditions at the same time point, and && p < 0.01, &&& p < 0.001represents statistical
significance between conditions among cell lines.
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Ovarian cancer cells express higher levels of folate receptor than normal cells [64], and folate 
receptor-targeted therapy is a way of directing nanoparticles to ovarian cancer cells both in vitro 
and in vivo [65]. Thus, as an attempt to improve the specificity of SeChry toward ovarian cancer 
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Figure 5. SeChry inhibits human cystathionine β-synthase H2S-synthesizing activity. Cystathionine
β-synthase (CBS)-catalyzed H2S production detected by the methylene blue assay, measured as a
function of SeChry concentration in the 0–200-µM range. Data from four independent experiments
(triplicates of each reaction and respective control) were fitted to a log10[inhibitor] versus normalized
response curve, yielding an apparent half maximal inhibitory concentration (IC50) of 6.3 ± 1.2 µM.
3.7. SeChry Delivery by PUREG4-FA Nanoparticles Allows the More Specific Targeting of Ovarian Cancer
Cells, While Reducing Cytotoxicity in Non-Malignant Cells
Ovarian cancer cells express higher levels of folate receptor than normal cells [64], and folate
receptor-targeted therapy is a way of directing nanoparticles to ovarian cancer cells both in vitro and
in vivo [65]. Thus, as an attempt to improve th pecifici y of SeChry toward ovarian cancer cells,
folat r ceptor-targ ted delivery of SeChry was performed using SeChry@PUREG4-FA nanoparticles as
a drug deli ery system. Cells were exposed to encapsulat d SeChry (SeChry@PUREG4-FA) alone or in
combination with cysteine nd/or carboplatin, and cell death was assessed by flow cytometry. Results
showed that SeChry@PUREG4-FA maintained cytotoxicity for ovarian cancer cells (ES2, OVCAR3, and
OVCAR8), though showing lower levels of cell death (Figure 6A–C). N tably, the previously obs rved
reversion of SeChry toxicity upon carboplatin exposure in both ES2 and OVCAR3 cells (Figure 2A,B)
was not observed with SeChry@PUREG4-FA nanoparticles (Figure 6A,B). In OVCAR8 cells, carboplatin
also did not interfere with the cytotoxic effect of SeChry@PUREG4-FA nanoparticles (Figure 6C).
Considering HaCaT and HK2 cells, strikingly, SeChry@PUREG4-FA nanoparticles presented lower
toxicity (Figure 6D,E) as compared to free SeChry (Figure 2C,D). Importantly, we observed significantly
higher levels of cell death in three ovarian cancer cell lines compared to non-malignant cells, mainly
keratinocytes, upon SeChry@PUREG4-FA nanoparticle exposure (Figure 6F).
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Figure 6. SeChry and folate-targeted polyurea dendrimer generation four (SeChry@PURE 4-FA)
nanoparticles increase specificity to ovarian cancer cells. All cell lines (ES2, OVCAR3, OVCAR8,
HaCaT, and HK2) were exposed to DMSO (control), cysteine, carboplatin, SeChry@PUREG4-FA,
and SeChry@PUREG4-FA combined with cysteine and/or carboplatin for 24 h and 48 h of
SeChry@PUREG4-FA exposure (A–E). Cell death was analyzed by flow cytometry using annexin
V–FITC and propidium iodide (PI) staining. SeChry@PUREG4-FA and SeChry@PUREG4-FA combined
with cysteine and/or carboplatin conditions were compared between cell lines (F). Results are shown as
means ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, and represents statistical significance in relation to
control conditions, and # p < 0.05, ## p < 0.01, ### p < 0.001represents statistical significance between
conditions (one-way ANOVA, Tukey post-test).
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4. Discussion
In ovarian cancer, chemoresistance is a major hindrance for a cure. Thus, the identification of
relevant players in the chemoresistance mechanisms is a key step to unveil the ovarian cancer response
to therapeutics [8,14,66,67] In this study, in line with our previous observations [25,57], cysteine
exhibited a protective role from carboplatin-induced cytotoxicity (Figure 1A,B). As oxidative/alkylating
agents, platinum drugs are responsible for GSH decrease through direct chemical interactions, leading
to the formation of GSH conjugates, as well as ROS [9,66,67]. Indeed, the combination of high
GSH doses with platinum protects cells against cisplatin-induced toxicity [68]. Therefore, cysteine
bioavailability is undoubtedly a motor for drug detoxification through both GSH synthesis and as a
precursor of H2S generation.
The xCT expression is intimately correlated with chemoresistance, which relies on xCT
overexpression and consequently increased cyst(e)ine uptake [23,69,70]. The role of xCT in cancer is
extensively characterized in the central nervous system context [19,21,71,72], regarding essentially
glutamate export, which also requires cyst(e)ine import. Herein, we observed that xCT expression in ES2
ovarian cancer cells is transcriptionally induced by cysteine and carboplatin (Figure 1C), with matching
protein levels in cells exposed to both cysteine and carboplatin (Figure 1D). Interestingly, the same was
observed for Nrf2 (Figure 1E,F), a major player in the cellular oxidative stress response and the main
regulator of xCT/SLC7A11 expression [23,29]. We, therefore, hypothesize that oxidative stress caused
by drug exposure triggers Nrf2 expression and activity, while the resulting GSH depletion is indirectly
responsible for increasing the Nrf2-regulated expression of genes involved in the antioxidant response.
It was previously reported that Nrf2 dissociation from Kelch-like ECH-associated protein 1 (Keap1)
and subsequent binding to antioxidant response element (ARE) regions (present in xCT/SLC7A11
promoter region) are responsible for triggering a cytoprotective adaptive response [23,73–75]. Whether
Nrf2 directly regulates xCT expression in ES2 and OVCAR3 cells needs further confirmation.
Notably, H2S metabolism is also mediated by Nrf2 via a regulatory loop. Whereas Nrf2 controls
the expression of CBS, cystathionine γ-lyase (another major H2S synthase), and sulfide/quinone
oxidoreductase (H2S-detoxifying enzyme), H2S activates Nrf2 via Keap1 inactivation through
persulfidation of Cys226 and Cys613 [76]. Moreover, endogenous overexpression of CBS and the resulting
increased H2S production in ovarian cancer cell lines are associated with metabolic reprogramming,
mitochondrial morphogenesis, and chemoresistance [12,26–28,77]. In line with this Nrf2–Cys–H2S
regulatory axis, increased xCT and Nrf2 expressions are fully compatible with our previous reports
unraveling that ovarian clear cell carcinoma cells (ES2) are especially dependent on cysteine metabolism
compared to ovarian serous carcinomas (OVCAR3), to cope with stressful conditions such as hypoxia
and drugs [25,57].
As selenium is also transported by xCT [23,43], we hypothesized that selenium compounds are
able to impair cysteine uptake. Albeit having antioxidant properties, selenium can also function as
a pro-oxidant and exhibit toxicity toward tumor cells [40,42]. In the present study, we focused on
the selenium–chrysin (SeChry) compound [42,48], which was described as having anti-tumor effects,
even without selenium [42,48,49]. Despite ES2 and OVCAR3 cells exhibiting comparable sensitivity
to SeChry-induced toxicity as determined by their EC50 values, the percentage of cell death upon
exposure to 19 µM SeChry was higher in OVCAR3 than in ES2 cells. This is in agreement with
our previous data showing that ES2 cells, when compared to OVCAR3, produce higher GSH levels
and in a more efficient way upon exposure to drugs [22]. Notwithstanding, SeChry also induced
cell death in non-malignant cell lines (Figure 2A–D), which could be explained by the recognized
pro-oxidant role of selenium compounds, based on ROS generation, protein oxidation, and DNA
binding, leading to impaired protein function, DNA damage, and cell death [42,48]. It was already
shown that selenium compounds present antioxidant or pro-oxidant properties depending on their
concentrations [45,78]. Interestingly, carboplatin abrogated SeChry cytotoxicity in ovarian cancer cells
exposed to both compounds (Figure 2A,B). These results highlight that SeChry could be useful in the
ovarian cancer clinical context but not if used concurrently with carboplatin administration. Strikingly,
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the protective effect of carboplatin upon SeChry exposure was not observed in non-malignant cells
(Figure 2C,D), further indicating that SeChry is probably acting through different mechanisms in cancer
and non-cancer cells. Another possibility is that carboplatin induces the cellular antioxidant responses
in the malignant cells but not in the non-malignant ones, leading to a higher antioxidant response to
SeChry. In addition to leading to cell death, SeChry increased xCT protein levels (Figure 2E), consistently
with what was observed in other in vitro cancer models, associating a higher xCT activity with higher
selenium salt (selenite) sensitivity [47]. These results are in line with what was previously reported
about the association of SeChry cytotoxicity with changes in mitochondrial membrane potential [48],
also consistent with increased oxidative stress. Indeed, whereas SeChry did not competitively inhibit
the xCT-mediated cyst(e)ine uptake, it induced GSH degradation (Figure 4A–F) [15]. Accordingly, the
extracellular concentrations of GSH and Cys-Gly, the first GSH degradation product, were generally
increased in cells exposed to SeChry compared to control conditions (Figure 4C–F). Those increased
extracellular GSH and Cys-Gly levels could, in turn, partially explain the decreased cell death observed
upon the combined exposure of SeChry and carboplatin, as their extracellular chemical interactions
could abrogate the effect of carboplatin and/or SeChry. Moreover, the Cys-Gly/GSH ratio (Figure 4G,H)
shows that ES2 and OVCAR3 are equally subjected to GSH depletion. Collectively, our data strongly
support the pro-oxidative role of SeChry in ovarian cancer cells (Figure 4) leading to GSH depletion.
The reduction of GSH content observed mainly in OVCAR3 cells is in accordance with Martins et al. [48].
While the increased intracellular Cys availability observed in ES2 cells could sustain an increased
production of the antioxidant H2S that could further counteract the pro-oxidant role of SeChry, the
enzyme inhibition assays showed otherwise. Although we did not address SeChry effects in CBS
inhibition in our cell models, we can speculate that this effect is stronger in ovarian cancer cells, as
CBS was reported to be involved in the promotion of ovarian tumor growth, cisplatin resistance, and
cellular bioenergetics [27], as well as in the regulation of mitochondria morphogenesis, promoting
tumor progression in ovarian cancer [26]. Neatly, we unraveled that SeChry is a specific and relatively
potent inhibitor of CBS. In fact, our data support that, while inhibiting CBS activity, 200 µM SeChry did
not inhibit CSE or MST (Figure 5). CBS inhibition was suggested as an appealing strategy to combat
chemoresistance in ovarian cancer [12,27,28], and as a generally valid anti-cancer approach [12,79].
In addition to the mechanistic relevance and pharmacological potential of SeChry in terms of additional
therapeutic options for ovarian cancer, the discovery of a specific and relatively potent CBS inhibitor
that does not inhibit CSE or MST should constitute a valuable research tool for the H2S field.
Despite the encouraging results obtained for SeChry against ovarian cancer cells, the observed cell
death in non-malignant cells, HaCaT and HK2, is not desirable for an anti-cancer drug. To overcome this,
we attempted a nanoparticle-based strategy. Nanoparticles are increasingly being used as drug carriers
to increase the efficiency of delivery to cancer cells, thus minimizing their accumulation in surrounding
tissues and the consequent side effects [80,81], while also decreasing chemoresistance [55,82]. Hence,
we tested an encapsulated SeChry formulation, using polyurea dendrimers surface-functionalized
with folate (SeChry@PUREG4-FA). Polyurea dendrimers are three-dimensional (3D) polymers bearing
urea moieties in the backbone and peripheral amine groups, belonging to a family of water-soluble,
biocompatible, biodegradable, pH-sensitive, intrinsically fluorescent polymers, presenting low toxicity
in all studied generations (up to the sixth generation) without affecting cell viability [53]. As cancer
cells express higher folate receptor levels [82,83], SeChry@PUREG4-FA may specifically deliver SeChry
to ovarian cancer cells (ES2, OVCAR3, and OVCAR8), reducing toxicity in non-malignant cells.
In fact, SeChry@PUREG4-FA induced significantly higher levels of cell death in ovarian cancer cells as
compared to non-malignant cells (Figure 6). Notably, with this formulation, a reversion of SeChry
toxicity upon carboplatin exposure was not observed in ovarian cancer cells, thus supporting its use
along with platinum drugs when encapsulated. These different interactions of free SeChry versus
encapsulated SeChry with carboplatin merits further attention in order to understand the mechanisms
behind SeChry cytotoxicity abrogation by carboplatin.
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uptake, we chose to test selenium-containing chrysin (SeChry) as a competitive inhibitor of xCT. (C) 
SeChry revealed to be toxic to ovarian cancer and non-malignant cells, albeit without impairing 
cyst(e)ine uptake. On the contrary, it increased GSH turnover and also inhibited cystathionine β-
synthase (CBS), an H2S producing enzyme. (D) The cytotoxic effect of SeChry was abrogated by 
carboplatin in ovarian cancer cells, but not in non-malignant cells, probably due to the chemical 
interaction between the two compounds. (E) The selective delivery of SeChry encapsulated in a 
folate-targeted polyurea dendrimer nanoparticle (SeChry@PUREG4-FA) presents higher cytotoxicity 
Figure 7. The central role of xCT transporter in chemoresistance and SeChry@PUREG4-FA as a new
drug to treat ovarian cancer. (A) Putative effects of cyst(e)ine (cystine and cysteine) in platinum salt
chemoresistance (carboplatin) by contributing to the bioavailability of glutathione (GSH), detoxifying
drugs, and reactive oxygen species (ROS), contributing also to the production of H2S, supplying oxidative
phosphorylation (OXPHOS). Oxidized GSH (GSSG) is exported through the action of glutathione
transferase (GST) Exposure to carboplatin, putatively, activates xCT/SLC7A11 transcription under the
action of Nrf2. (B) We hypothesized that, by disturbing cyst(e)ine metabolic flux, chemoresistance
would be reverted. Since the xCT transporter is also responsible for selenium uptake, we chose to
test selenium-containing chrysin (SeChry) as a competitive inhibitor of xCT. (C) SeChry revealed
to be toxic to ovarian cancer and non-malignant cells, albeit without impairing cyst(e)ine uptake.
On the contrary, it increased GSH turnover and also inhibited cystathionine β-synthase (CBS), an
H2S producing enzyme. (D) The cytotoxic effect of SeChry was abrogated by carboplatin in ovarian
cancer cells, but not in non-malignant cells, probably due to the chemical interaction between the two
compounds. (E) The selective delivery of SeChry encapsulated in a folate-targeted polyurea dendrimer
nanoparticle (SeChry@PUREG4-FA) presents higher cytotoxicity to ovarian cancer cells compared to
non-malignant cells and avoids SeChry inactivation by carboplatin. We propose SeChry@PUREG4-FA
as a new drug formulation to treat ovarian cancer.
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5. Conclusions
Collectively, our study supports SeChry@PUREG4-FA as a new targeted drug formulation with
promising results in ovarian cancer treatment, a highly lethal disease largely due to the lack of an
effective therapy. We disentangled two mechanisms of action of SeChry: increased oxidative stress
prompting GSH depletion, and inhibition of the H2S-generating enzyme CBS, while upregulating xCT
expression (Figure 7). Despite SeChry degradation not being observed in culture media, and other
studies not describing deselenization for other selenium derivatives [84], the generation of SeChry
diselenide derivatives and metabolites must be further investigated in order to fully characterize the
metabolism of SeChry and the mechanisms underlying its cytotoxicity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/10/2523/s1,
Figure S1: Determination of SeChry EC50 for ES2 and OVCAR3 cell Lines. The effective concentration 50 (EC50)
was determined based on the cell death levels induced by different concentration of selenium-chrysin (SeChry)
in ovarian cell lines. Cell death was determined by flow cytometry, measuring annexin V-FITC and propidium
iodide (PI) levels.
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